Latest News

Filters

Filter by tags: South Korea CANDU reactor Clear all tag filters

14 news articles found

France’s Framatome and Korea Hydro & Nuclear Power (KHNP) have signed a memorandum of understanding (MOU) to demonstrate the feasibility of producing non-carrier added lutetium-177 (Lu-177) at South Korea’s Wolsong NPP. Framatome and KHNP will jointly perform this technical assessment at the plant using Framatome’s isotope production technology. This has been successfully implemented on a commercial production level at the Bruce Power NPP in Canada.

Source: NEI Magazine
Date: Thursday, 25 April 2024
Original article: neimagazine.com/news/newsframatome-and-khnp-to-assess-feasibility-of-medical-isotope-production-at-wolsong-11708951

Framatome and Korea Hydro & Nuclear Power (KHNP) are to assess the feasibility of producing medical isotope lutetium-177 in the Candu pressurised heavy water reactors at the Wolsong nuclear power plant in South Korea.

Source: World Nuclear News
Date: Friday, 19 April 2024
Original article: world-nuclear-news.org/Articles/Framatome,-KHNP-to-cooperate-on-medical-isotope-pr

An International Atomic Energy Agency (IAEA) Pre-SALTO (Safety Aspects of Long Term Operation) review mission has completed a review of long term operational safety at unit 1 of the Cernavoda Nuclear NPP at the request of plant’s operator, SN Nuclearelectrica (SNN). Cernavoda 1 went into commercial operation in 1996. It is one of two 700 MWe Candu-6 pressurised heavy water reactors at the NPP. SNN is planning to refurbish the reactor and extend the total operating lifetime to approximately 60 years.

Source: NEI Magazine
Date: Wednesday, 13 March 2024
Original article: neimagazine.com/news/newsiaea-reviews-long-term-operational-safety-at-romanias-cernavoda-npp-11594409

Bucharest also planning two new Candu plants at site

Source: Nucnet
Date: Tuesday, 20 February 2024
Original article: nucnet.org/news/italy-s-ansaldo-energia-secures-financing-for-cernavoda-1-lifetime-extension-work-2-1-2024

Korea Hydro & Nuclear Power (KHNP) announced it has signed an agreement with Canada's Candu Energy and Italy's Ansaldo Nucleare to jointly carry out a refurbishment of unit 1 at the Cernavoda nuclear power plant in Romania.

Source: World Nuclear News
Date: Saturday, 14 October 2023
Original article: world-nuclear-news.org/Articles/Multinational-consortium-formed-for-Cernavoda-work

Romanian nuclear utility Societatea Nationala Nuclearelectrica (SNN), and Korea Hydro & Nuclear Power (KHNP) have signed an Engineering, Procurement & Construction (EPC) contract for construction of the Cernavoda Tritium Removal Facility (CTRF).

Source: NEI Magazine
Date: Friday, 30 June 2023
Original article: neimagazine.com/news/newsnuclearelectrica-and-khnp-to-construct-tritium-removal-facility-at-cernavoda-npp-10974947

The director of the Jordan Atomic Energy Commission (JAEC) Khaled Touqan, said, looking forward to the next 10 years, JAEC is considering small reactors. It is looking at various possibilities including designs from Russia, Korea, France, and the UK, trying to determine the optimal technical specifications and how to adapt such reactors to the Jordanian environment, Touqan explained. He noted the potential use of small nuclear reactors for water desalination as well as power production.

Source: NEI Magazine
Date: Saturday, 29 April 2023
Original article: neimagazine.com/news/newsjordan-considers-floating-npps-10798331

Advances in emerging field of ‘theranostics’ are a game-changer Millions of patients around the globe rely on the regular and timely production of diagnostic and therapeutic isotopes produced in research reactors and accelerator facilities. Image courtesy IAEA. Advances in medical isotope diagnostics and therapy are holding promise for cancer patients, despite challenges facing the nuclear medical field in recent years related to radionuclide production and supply, rising costs, and stricter regulation.

Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.

Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.

According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.

Source: Nucnet
Date: Friday, 14 April 2023
Original article: nucnet.org/news/sector-aims-to-tackle-isotope-supply-problems-as-excitement-grows-over-targeted-therapies-4-4-2023

In a wide ranging interview for the World Nuclear News podcast, Cameco CEO Tim Gitzel explained: Why the time was right for the Westinghouse deal How Russia's war with Ukraine has led to 'bifurcation' of the nuclear sector Explained Cameco's long-term strategy Looks ahead at the impact of new technologies, including SMRs How nuclear will need to play a key role in getting to net-zero

Source: World Nuclear News
Date: Wednesday, 09 November 2022
Original article: world-nuclear-news.org/Articles/In-Quotes-Cameco-s-Tim-Gitzel-WNN-podcast-on-nucle

A Memorandum of Understanding (MoU) between Framatome and Exelon Generation will see the two companies work towards the production of cobalt-60 (Co-60) in pressurised water reactors (PWRs) for medical and industrial uses.

Source: World Nuclear News
Date: Thursday, 06 January 2022
Original article: world-nuclear-news.org/Articles/Framatome-and-Exelon-to-explore-Co-60-production

Load more news